文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

自身免疫性胃炎:幽门螺杆菌阴性初治患者的长期自然史

Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients.
PubMed 文献 · Gut · 2022-06-30

这项前瞻性长期随访研究纳入211例经血清学、组织学和分子生物学检测确认幽门螺杆菌阴性的自身免疫性胃炎患者,配对活检显示胃体为主单核细胞炎症、假幽门腺化生多于肠化生,ECL细胞增生/异型增生可进展,Type1-NETs与广泛胃体萎缩并存,累计随访10541人年未发现胃癌风险增加。

要点

  • 幽门螺杆菌阴性自身免疫性胃炎以胃体为主单核细胞炎症、假幽门腺化生和ECL细胞增生/肿瘤为组织学标志。
  • 假幽门腺化生多于肠化生,肠化生评分从T1到T2增加而假幽门腺化生患病率无变化。
  • 累计随访10541人年未见胃癌或其他恶性肿瘤风险增加,仅甲状腺癌风险边缘显著升高。

核心结论

  • 胃体为主炎症、假幽门腺化生(多于肠化生)和ECL细胞增生/肿瘤是自身免疫性胃炎的組織學标志。
  • 与一般人群相比,胃体为主炎症/萎缩不增加胃癌风险;文献报告的自身免疫性胃炎患者胃癌风险增加可能源于未识别的既往或当前幽门螺杆菌合并感染。

研究设计与样本

  • 前瞻性长期随访研究,纳入211例经血清学、组织学和分子生物学检测确认幽门螺杆菌阴性的自身免疫性胃炎患者(女:男=3.15:1;p<0.001)。
  • 配对活检(T1 vs T2),平均随访7.5年(SD:4.4),中位随访7年。

主要发现

  • T1时假幽门腺化生评分高于肠化生(分别为200/211 vs 160/211)。
  • 肠化生评分从T1到T2增加(从160/211增至179/211),假幽门腺化生患病率无变化(T1=200/211;T2=201/211)。
  • T1和T2时OLGA-III期患病率均<5%,未出现OLGA-IV期。
  • ECL细胞状态从弥漫性增生进展为腺瘤样增生/异型增生(T1=167/14 vs T2=151/25)。
  • Type1-NETs(T1=10;T2=11)始终与广泛胃体萎缩及ECL腺瘤样增生/异型增生共存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Autoimmune gastritis (AIG) is an immunomediated disease targeting parietal cells, eventually resulting in oxyntic-restricted atrophy. This long-term follow-up study aimed at elucidating the natural history, histological phenotype(s), and associated cancer risk of patients with AIG consistently tested H. pylori-negative (naïve H. pylori-negative subjects). DESIGN: Two-hundred eleven naïve H. pylori-negative patients (tested by serology, histology, molecular biology) with AIG (F:M=3.15:1; p<0.001) were prospectively followed up with paired biopsies (T1 vs T2; mean follow-up years:7.5 (SD:4.4); median:7). Histology distinguished non-atrophic versus atrophic AIG. Atrophy was further subtyped/scored as non-metaplastic versus metaplastic (pseudopyloric (PPM) and intestinal (IM)). Enterochromaffin-like-cell (ECL) status was categorised as diffuse versus adenomatoid hyperplasia/dysplasia, and type 1 neuroendocrine tumours (Type1-NETs). RESULTS: Over the long-term histological follow-up, AIG consistently featured oxyntic-predominant-mononuclear inflammation. At T1, PPM-score was greater than IM (200/211 vs 160/211, respectively); IM scores increased from T1 to T2 (160/211 to 179/211), with no changes in the PPM prevalence (T1=200/211; T2=201/211). At both T1/T2, the prevalence of OLGA-III-stage was <5%; no Operative Link on Gastritis Assessment (OLGA)-IV-stage occurred. ECL-cell-status progressed from diffuse to adenomatoid hyperplasia/dysplasia (T1=167/14 vs T2=151/25). Type1-NETs (T1=10; T2=11) always coexisted with extensive oxyntic-atrophy, and ECL adenomatoid-hyperplasia/dysplasia. No excess risk of gastric or other malignancies was found over a cumulative follow-up time of 10 541 person years, except for (marginally significant) thyroid cancer (SIR=3.09; 95% CI 1.001 to 7.20). CONCLUSIONS: Oxyntic-restricted inflammation, PPM (more than IM), and ECL-cell hyperplasia/neoplasia are the histological AIG hallmarks. Compared with the general population, corpus-restricted inflammation/atrophy does not increase the GC risk. The excess of GC risk reported in patients with AIG could plausibly result from unrecognised previous/current H. pylori comorbidity.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Rugge M, Bricca L, Guzzinati S, et al. Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients. Gut. 2022. PMID: 35772926. doi:10.1136/gutjnl-2022-327827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。